Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes

You'll hear buzz about using SGLT2 inhibitors (empagliflozin, etc) in patients withOUT diabetes...for heart failure or kidney disease.

That's because growing evidence suggests these meds may improve outcomes when added to standard therapy.

In heart failure with reduced ejection fraction (HFrEF), adding empagliflozin (Jardiance) over 16 months prevents hospitalization or CV death in about 1 in 14 type 2s...or 1 in 26 patients withOUT diabetes.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals